Antimicrobial Therapy of Sepsis and Septic Shock-When Are Two Drugs Better Than One?

Critical Care Clinics

Volumn 27, Issue 2, 2011, Pages e1-

  Abad, Cybéle L ^a   Kumar, Anand ^b,c   Safdar, Nasia ^a  

^a University of Wisconsin Health   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

^c WINNIPEG REGIONAL HEALTH AUTHORITY   (Canada)

Author keywords

Bacteremia; Combination anti infective therapy; Pneumonia; Sepsis

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; CLINDAMYCIN; DAPTOMYCIN; ERTAPENEM; FLEROXACIN; FLUCLOXACILLIN; GENTAMICIN; IMIPENEM; LATAMOXEF; LEVOFLOXACIN; MACROLIDE; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ABDOMINAL INFECTION; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; BACTERIAL ENDOCARDITIS; BACTERICIDAL ACTIVITY; BLOODSTREAM INFECTION; COMBINATION CHEMOTHERAPY; COMMUNITY ACQUIRED PNEUMONIA; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG WITHDRAWAL; GRAM NEGATIVE SEPSIS; GRAM POSITIVE INFECTION; HUMAN; INTENSIVE CARE UNIT; KIDNEY DYSFUNCTION; LOW DRUG DOSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MONOTHERAPY; MORTALITY; NEPHROTOXICITY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEPSIS; SEPTIC SHOCK; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS INFECTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME; TREATMENT RESPONSE; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 79953010135     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccc.2010.12.001     Document Type: Review

References (146)

1. Angus D.C., Linde-Zwirble W.T., Lidicker J., et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29(7):1303-1310.
2. Martin G.S., Mannino D.M., Eaton S., et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003, 348(16):1546-1554.
3. Wheeler A.P., Bernard G.R. Treating patients with severe sepsis. N Engl J Med 1999, 340(3):207-214.
4. Heron M., Hoyert D.L., Murphy S.L., et al. Deaths: final data for 2006. Natl Vital Stat Rep 2009, 57(14):1-134.
5. Pinder M., Bellomo R., Lipman J. Pharmacological principles of antibiotic prescription in the critically ill. Anaesth Intensive Care 2002, 30(2):134-144.
6. Solomkin J.S., Miyagawa C.I. Principles of antibiotic therapy. Surg Clin North Am 1994, 74(3):497-517.
7. Whipple J.K., Ausman R.K., Franson T., et al. Effect of individualized pharmacokinetic dosing on patient outcome. Crit Care Med 1991, 19(12):1480-1485.
8. Paul M., Benuri-Silbiger I., Soares-Weiser K., et al. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 2004, 328(7441):668.
9. Safdar N., Handelsman J., Maki D.G. Does combination antimicrobial therapy reduce mortality in gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004, 4(8):519-527.
10. Micek S.T., Welch E.C., Khan J., et al. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to gram-negative bacteria: a retrospective analysis. Antimicrob Agents Chemother 2010, 54(5):1742-1748.
11. Dellinger R.P., Levy M.M., Carlet J.M., et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008, 36(1):296-327.
12. den Hollander J.G., Horrevorts A.M., van Goor M.L., et al. Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1997, 41(1):95-100.
13. Giamarellou H., Zissis N.P., Tagari G., et al. In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 1984, 25(4):534-536.
14. Klastersky J., Zinner S.H. Synergistic combinations of antibiotics in gram-negative bacillary infections. Rev Infect Dis 1982, 4(2):294-301.
15. Mouton J.W. Combination therapy as a tool to prevent emergence of bacterial resistance. Infection 1999, 27(Suppl 2):S24-S28.
16. Wu Y.L., Scott E.M., Po A.L., et al. Ability of azlocillin and tobramycin in combination to delay or prevent resistance development in Pseudomonas aeruginosa. J Antimicrob Chemother 1999, 44(3):389-392.
17. Klastersky J., Meunier-Carpentier F., Prevost J.M. Significance of antimicrobial synergism for the outcome of gram negative sepsis. Am J Med Sci 1977, 273(2):157-167.
18. Calandra T., Glauser M.P. Immunocompromised animal models for the study of antibiotic combinations. Am J Med 1986, 80(5C):45-52.
19. Darras-Joly C., Bedos J.P., Sauve C., et al. Synergy between amoxicillin and gentamicin in combination against a highly penicillin-resistant and -tolerant strain of Streptococcus pneumoniae in a mouse pneumonia model. Antimicrob Agents Chemother 1996, 40(9):2147-2151.
20. Kumar A., Mensing J., Zelenitsky S. Effect of antibiotic sequence on blood bacterial counts in a rat model of E. coli peritonitis/septic shock. ICAAC Proc 2004, 26:A-1296.
21. Anderson E.T., Young L.S., Hewitt W.L. Antimicrobial synergism in the therapy of gram-negative rod bacteremia. Chemotherapy 1978, 24(1):45-54.
22. Bouza E., Munoz P. Monotherapy versus combination therapy for bacterial infections. Med Clin North Am 2000, 84(6):1357-1389. v.
23. De Jongh C.A., Joshi J.H., Newman K.A., et al. Antibiotic synergism and response in gram-negative bacteremia in granulocytopenic cancer patients. Am J Med 1986, 80(5C):96-100.
24. Paul M., Silbiger I., Grozinsky S., et al. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 2006, 1. CD003344.
25. Kumar A., Safdar N., Kethireddy S., et al. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta-regression study. Crit Care Med 2010, 38(8):1651-1664.
26. Bone R.C., Balk R.A., Cerra F.B., et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101(6):1644-1655.
27. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992, 20(6):864-874.
28. Vincent J.L., Korkut H.A. Defining sepsis. Clin Chest Med 2008, 29(4):585-590. vii.
29. Levy M.M., Fink M.P., Marshall J.C., et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003, 31(4):1250-1256.
30. Bochud P.Y., Bonten M., Marchetti O., et al. Antimicrobial therapy for patients with severe sepsis and septic shock: an evidence-based review. Crit Care Med 2004, 32(Suppl 11):S495-S512.
31. Sands K.E., Bates D.W., Lanken P.N., et al. Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA 1997, 278(3):234-240.
32. Brun-Buisson C., Doyon F., Carlet J., et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA 1995, 274(12):968-974.
33. Kumar A., Ellis P., Arabi Y., et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009, 136(5):1237-1248.
34. Kumar A., Roberts D., Wood K.E., et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34(6):1589-1596.
35. Edmond M.B., Wallace S.E., McClish D.K., et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999, 29(2):239-244.
36. Pfaller M.A., Jones R.N., Messer S.A., et al. National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagn Microbiol Infect Dis 1998, 31(1):327-332.
37. Bochud P.Y., Glauser M.P., Calandra T. Antibiotics in sepsis. Intensive Care Med 2001, 27(Suppl 1):S33-S48.
38. McCabe W.R., Jackson G.G. Gram negative bacteremia. Ann Intern Med 1962, 134:298-314.
39. Bryant R.E., Hood A.F., Hood C.E., et al. Factors affecting mortality of gram-negative rod bacteremia. Arch Intern Med 1971, 127(1):120-128.
40. Chow J.W., Fine M.J., Shlaes D.M., et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991, 115(8):585-590.
41. Freid M.A., Vosti K.L. The importance of underlying disease in patients with gram-negative bacteremia. Arch Intern Med 1968, 121(5):418-423.
42. Kreger B.E., Craven D.E., McCabe W.R. Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients. Am J Med 1980, 68(3):344-355.
43. Leibovici L., Paul M., Poznanski O., et al. Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother 1997, 41(5):1127-1133.
44. Schiappa D.A., Hayden M.K., Matushek M.G., et al. Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation. J Infect Dis 1996, 174(3):529-536.
45. Vidal F., Mensa J., Almela M., et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch Intern Med 1996, 156(18):2121-2126.
46. Young L.S., Martin W.J., Meyer R.D., et al. Gram-negative rod bacteremia: microbiologic, immunologic, and therapeutic considerations. Ann Intern Med 1977, 86(4):456-471.
47. Kollef M.H., Sherman G., Ward S., et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999, 115(2):462-474.
48. Garnacho-Montero J., Garcia-Garmendia J.L., Barrero-Almodovar A., et al. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003, 31(12):2742-2751.
49. Chow J.W., Yu V.L. Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. Int J Antimicrob Agents 1999, 11(1):7-12.
50. Giamarellou H. Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions. Am J Med 1986, 80(6B):126-137.
51. Moellering R.C., Eliopoulos G.M., Allan J.D. Beta-lactam/aminoglycoside combinations: interactions and their mechanisms. Am J Med 1986, 80(5C):30-34.
52. Manian F.A., Meyer L., Jenne J., et al. Loss of antimicrobial susceptibility in aerobic gram-negative bacilli repeatedly isolated from patients in intensive-care units. Infect Control Hosp Epidemiol 1996, 17(4):222-226.
53. Weinstein R.A. Occurrence of cefotaxime-resistant Enterobacter during therapy of cardiac surgery patients. Chemioterapia 1985, 4(1):110-112.
54. Safdar N., Abad C. Combination antimicrobial therapy for gram-negative infections: what is the evidence?. Antimicrobial resistance problem pathogens and clinical countermeasures 2008, 433-459. Informa Healthcare USA, Inc, New York. R. Owens, E. Lautenbach (Eds.).
55. Bergmans D.C., Bonten M.J., Gaillard C.A., et al. Indications for antibiotic use in ICU patients: a one-year prospective surveillance. J Antimicrob Chemother 1997, 39(4):527-535.
56. Cook D.J., Kollef M.H. Risk factors for ICU-acquired pneumonia. JAMA 1998, 279(20):1605-1606.
57. Vincent J.L., Bihari D.J., Suter P.M., et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995, 274(8):639-644.
58. Warren D.K., Shukla S.J., Olsen M.A., et al. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med 2003, 31(5):1312-1317.
59. Fagon J.Y., Chastre J., Hance A.J., et al. Evaluation of clinical judgment in the identification and treatment of nosocomial pneumonia in ventilated patients. Chest 1993, 103(2):547-553.
60. Heyland D.K., Cook D.J., Griffith L., et al. The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group. Am J Respir Crit Care Med 1999, 159(4 Pt 1):1249-1256.
61. Safdar N., Dezfulian C., Collard H.R., et al. Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med 2005, 33(10):2184-2193.
62. Singh N., Rogers P., Atwood C.W., et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000, 162(2 Pt 1):505-511.
63. American Thoracic Society, Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171(4):388-416.
64. Aarts M.A., Hancock J.N., Heyland D., et al. Empiric antibiotic therapy for suspected ventilator-associated pneumonia: a systematic review and meta-analysis of randomized trials. Crit Care Med 2008, 36(1):108-117.
65. Chapman T.M., Perry C.M. Cefepime: a review of its use in the management of hospitalized patients with pneumonia. Am J Respir Med 2003, 2(1):75-107.
66. Jaccard C., Troillet N., Harbarth S., et al. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 1998, 42(11):2966-2972.
67. Nicolau D.P., McNabb J., Lacy M.K., et al. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents 2001, 17(6):497-504.
68. Rubinstein E., Lode H., Grassi C. Ceftazidime monotherapy vs. ceftriaxone/tobramycin for serious hospital-acquired gram-negative infections. Antibiotic Study Group. Clin Infect Dis 1995, 20(5):1217-1228.
69. Sieger B., Berman S.J., Geckler R.W., et al. Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study. Meropenem Lower Respiratory Infection Group. Crit Care Med 1997, 25(10):1663-1670.
70. West M., Boulanger B.R., Fogarty C., et al. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study. Clin Ther 2003, 25(2):485-506.
71. Angus D.C., Marrie T.J., Obrosky D.S., et al. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. Am J Respir Crit Care Med 2002, 166(5):717-723.
72. Bodi M., Rodriguez A., Sole-Violan J., et al. Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival. Clin Infect Dis 2005, 41(12):1709-1716.
73. Fine M.J., Smith M.A., Carson C.A., et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996, 275(2):134-141.
74. Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(Suppl 2):S27-S72.
75. Ramirez J.A. Worldwide perspective of the quality of care provided to hospitalized patients with community-acquired pneumonia: results from the CAPO international cohort study. Semin Respir Crit Care Med 2005, 26(6):543-552.
76. Blot S., Depuydt P. Antibiotic therapy for community-acquired pneumonia with septic shock: follow the guidelines. Crit Care Med 2007, 35(6):1617-1618.
77. Baddour L.M., Yu V.L., Klugman K.P., et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004, 170(4):440-444.
78. Mufson M.A., Stanek R.J. Bacteremic pneumococcal pneumonia in one American city: a 20-year longitudinal study, 1978-1997. Am J Med 1999, 107(1A):34S-43S.
79. Waterer G.W., Somes G.W., Wunderink R.G. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001, 161(15):1837-1842.
80. Weiss K., Low D.E., Cortes L., et al. Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults. Can Respir J 2004, 11(8):589-593.
81. Rodriguez A., Mendia A., Sirvent J.M., et al. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med 2007, 35(6):1493-1498.
82. Lodise T.P., Kwa A., Cosler L., et al. Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia. Antimicrob Agents Chemother 2007, 51(11):3977-3982.
83. Chokshi R., Restrepo M.I., Weeratunge N., et al. Monotherapy versus combination antibiotic therapy for patients with bacteremic Streptococcus pneumoniae community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2007, 26(7):447-451.
84. Feldman C., Anderson R. Therapy for pneumococcal bacteremia: monotherapy or combination therapy?. Curr Opin Infect Dis 2009, 22(2):137-142.
85. Healy D.P. Macrolide immunomodulation of chronic respiratory diseases. Curr Infect Dis Rep 2007, 9(1):7-13.
86. Fowler V.G., Boucher H.W., Corey G.R., et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006, 355(7):653-665.
87. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992-April 2000, issued June 2000. Am J Infect Control 2000, 28(6):429-448.
88. Wisplinghoff H., Bischoff T., Tallent S.M., et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004, 39(3):309-317.
89. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004, 32(8):470-485.
90. Hancock R.E., Speert D.P. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and impact on treatment. Drug Resist Updat 2000, 3(4):247-255.
91. Feldman C., Smith C., Levy H., et al. Klebsiella pneumoniae bacteraemia at an urban general hospital. J Infect 1990, 20(1):21-31.
92. Hilf M., Yu V.L., Sharp J., et al. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 1989, 87(5):540-546.
93. Dworkin R.J., Lee B.L., Sande M.A., et al. Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin. Lancet 1989, 2(8671):1071-1073.
94. Fowler V.G., Sanders L.L., Sexton D.J., et al. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clin Infect Dis 1998, 27(3):478-486.
95. Lautenschlager S., Herzog C., Zimmerli W. Course and outcome of bacteremia due to Staphylococcus aureus: evaluation of different clinical case definitions. Clin Infect Dis 1993, 16(4):567-573.
96. Zimmerli W., Widmer A.F., Blatter M., et al. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 1998, 279(19):1537-1541.
97. Olaison L., Schadewitz K. Enterococcal endocarditis in Sweden, 1995-1999: can shorter therapy with aminoglycosides be used?. Clin Infect Dis 2002, 34(2):159-166.
98. Sande M.A., Courtney K.B. Nafcillin-gentamicin synergism in experimental staphylococcal endocarditis. J Lab Clin Med 1976, 88(1):118-124.
99. Watanakunakorn C., Baird I.M. Prognostic factors in Staphylococcus aureus endocarditis and results of therapy with a penicillin and gentamicin. Am J Med Sci 1977, 273(2):133-139.
100. Geraci J.E., Martin W.J. Antibiotic therapy of bacterial endocarditis. VI. Subacute enterococcal endocarditis: clinical, pathologic and therapeutic consideration of 33 cases. Circulation 1954, 10(2):173-194.
101. Abrams B., Sklaver A., Hoffman T., et al. Single or combination therapy of staphylococcal endocarditis in intravenous drug abusers. Ann Intern Med 1979, 90(5):789-791.
102. Korzeniowski O., Sande M.A. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: a prospective study. Ann Intern Med 1982, 97(4):496-503.
103. Ribera E., Gomez-Jimenez J., Cortes E., et al. Effectiveness of cloxacillin with and without gentamicin in short-term therapy for right-sided Staphylococcus aureus endocarditis. A randomized, controlled trial. Ann Intern Med 1996, 125(12):969-974.
104. Coppens L., Hanson B., Klastersky J. Therapy of staphylococcal infections with cefamandole or vancomycin alone or with a combination of cefamandole and tobramycin. Antimicrob Agents Chemother 1983, 23(1):36-41.
105. Sexton D.J., Tenenbaum M.J., Wilson W.R., et al. Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillin-susceptible streptococci. Endocarditis Treatment Consortium Group. Clin Infect Dis 1998, 27(6):1470-1474.
106. Bayer A.S., Bolger A.F., Taubert K.A., et al. Diagnosis and management of infective endocarditis and its complications. Circulation 1998, 98(25):2936-2948.
107. Mandell G.L., Kaye D., Levison M.E., et al. Enterococcal endocarditis. An analysis of 38 patients observed at the New York Hospital-Cornell Medical Center. Arch Intern Med 1970, 125(2):258-264.
108. Moellering R.C., Watson B.K., Kunz L.J. Endocarditis due to group D streptococci. Comparison of disease caused by streptococcus bovis with that produced by the enterococci. Am J Med 1974, 57(2):239-250.
109. Rice L.B., Calderwood S.B., Eliopoulos G.M., et al. Enterococcal endocarditis: a comparison of prosthetic and native valve disease. Rev Infect Dis 1991, 13(1):1-7.
110. Vogler W.R., Dorney E.R., Bridges H.A. Bacterial endocarditis. A review of 148 cases. Am J Med 1962, 32:910-921.
111. Wilson W.R., Wilkowske C.J., Wright A.J., et al. Treatment of streptomycin-susceptible and streptomycin-resistant enterococcal endocarditis. Ann Intern Med 1984, 100(6):816-823.
112. Schrenzel J., Harbarth S., Schockmel G., et al. A randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection. Clin Infect Dis 2004, 39(9):1285-1292.
113. Rehm S.J., Boucher H., Levine D., et al. Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. J Antimicrob Chemother 2008, 62(6):1413-1421.
114. Cosgrove S.E., Vigliani G.A., Fowler V.G., et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis 2009, 48(6):713-721.
115. Pieracci F.M., Barie P.S. Management of severe sepsis of abdominal origin. Scand J Surg 2007, 96(3):184-196.
116. Barie P.S., Hydo L.J., Shou J., et al. Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis. Surg Infect (Larchmt) 2006, 7(Suppl 2):S77-S80.
117. Barie P.S., Vogel S.B., Dellinger E.P., et al. A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Cefepime Intra-abdominal Infection Study Group. Arch Surg 1997, 132(12):1294-1302.
118. Farthmann E.H., Schoffel U. Principles and limitations of operative management of intraabdominal infections. World J Surg 1990, 14(2):210-217.
119. Garcia-Sabrido J.L., Tallado J.M., Christou N.V., et al. Treatment of severe intra-abdominal sepsis and/or necrotic foci by an 'open-abdomen' approach. Zipper and zipper-mesh techniques. Arch Surg 1988, 123(2):152-156.
120. Montravers P., Chalfine A., Gauzit R., et al. Clinical and therapeutic features of nonpostoperative nosocomial intra-abdominal infections. Ann Surg 2004, 239(3):409-416.
121. Nathens A.B., Rotstein O.D., Marshall J.C. Tertiary peritonitis: clinical features of a complex nosocomial infection. World J Surg 1998, 22(2):158-163.
122. Roehrborn A., Thomas L., Potreck O., et al. The microbiology of postoperative peritonitis. Clin Infect Dis 2001, 33(9):1513-1519.
123. Montravers P., Gauzit R., Muller C., et al. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis 1996, 23(3):486-494.
124. Hoban D.J., Bouchillon S.K., Hawser S.P., et al. Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother 2010, 54(7):3031-3034.
125. Falagas M.E., Barefoot L., Griffith J., et al. Risk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infections. Eur J Clin Microbiol Infect Dis 1996, 15(12):913-921.
126. Mosdell D.M., Morris D.M., Voltura A., et al. Antibiotic treatment for surgical peritonitis. Ann Surg 1991, 214(5):543-549.
127. Solomkin J.S., Mazuski J.E., Baron E.J., et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003, 37(8):997-1005.
128. Yellin A.E., Hassett J.M., Fernandez A., et al. Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections in adults. Int J Antimicrob Agents 2002, 20(3):165-173.
129. Mazuski J.E., Sawyer R.G., Nathens A.B., et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: evidence for the recommendations. Surg Infect (Larchmt) 2002, 3(3):175-233.
130. Condon R.E., Walker A.P., Sirinek K.R., et al. Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial. Clin Infect Dis 1995, 21(3):544-550.
131. Dougherty S.H., Sirinek K.R., Schauer P.R., et al. Ticarcillin/clavulanate compared with clindamycin/gentamicin (with or without ampicillin) for the treatment of intra-abdominal infections in pediatric and adult patients. Am Surg 1995, 61(4):297-303.
132. Luke M., Iversen J., Sondergaard J., et al. Ceftriaxone/metronidazole is more effective than ampicillin/netilmicin/metronidazole in the treatment of bacterial peritonitis. Eur J Surg 1991, 157(6/7):397-401.
133. Poenaru D., De Santis M., Christou N.V. Imipenem versus tobramycin-antianaerobe antibiotic therapy in intra-abdominal infections. Can J Surg 1990, 33(5):415-422.
134. Angeras M.H., Darle N., Hamnstrom K., et al. A comparison of imipenem/cilastatin with the combination of cefuroxime and metronidazole in the treatment of intra-abdominal infections. Scand J Infect Dis 1996, 28(5):513-518.
135. Huizinga W.K., Baker L.W., Kadwa H., et al. Management of severe intra-abdominal sepsis: single agent antibiotic therapy with cefotetan versus combination therapy with ampicillin, gentamicin and metronidazole. Br J Surg 1988, 75(11):1134-1138.
136. Mehtar S., Dewar E.P., Leaper D.J., et al. A multi-centre study to compare meropenem and cefotaxime and metronidazole in the treatment of hospitalized patients with serious infections. J Antimicrob Chemother 1997, 39(5):631-638.
137. Ohlin B., Cederberg A., Forssell H., et al. Piperacillin/tazobactam compared with cefuroxime/ metronidazole in the treatment of intra-abdominal infections. Eur J Surg 1999, 165(9):875-884.
138. Cohn S.M., Lipsett P.A., Buchman T.G., et al. Comparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections. Ann Surg 2000, 232(2):254-262.
139. Solomkin J.S., Reinhart H.H., Dellinger E.P., et al. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group. Ann Surg 1996, 223(3):303-315.
140. Dupont H., Carbon C., Carlet J. Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: a multicenter randomized controlled trial. The Severe Generalized Peritonitis Study Group. Antimicrob Agents Chemother 2000, 44(8):2028-2033.
141. Fink M.P. Antibiotic therapy of intra-abdominal sepsis in the elderly: experience with ticarcillin and clavulanic acid. Surg Gynecol Obstet 1991, 172(Suppl):36-41.
142. Schentag J.J., Wels P.B., Reitberg D.P., et al. A randomized clinical trial of moxalactam alone versus tobramycin plus clindamycin in abdominal sepsis. Ann Surg 1983, 198(1):35-41.
143. Solomkin J.S., Dellinger E.P., Christou N.V., et al. Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections. Ann Surg 1990, 212(5):581-591.
144. Solomkin J., Zhao Y.P., Ma E.L., et al. Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections. Int J Antimicrob Agents 2009, 34(5):439-445.
145. Kumar A., Zarychanski R., Light B., et al. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med 2010, 38(9):1773-1785.
146. Comparison of two antibiotic regimens (Meropenem Versus Meropenem+Moxifloxacin) in the treatment of severe sepsis and septic shock Available at:, Accessed September1, 2010. http://www.clinicaltrial.gov.